Key Figures Q2 2021
|
SEK m, unless otherwise stated |
2021 Apr-Jun |
2020 Apr-Jun |
2021 Jan-Jun |
2020 Jan-Jun |
2020 Jan-Dec |
|
Net revenues |
142.8 |
179.1 |
275.1 |
354.2 |
663.6 |
|
Cost of goods sold |
-18.1 |
-19.9 |
-37.4 |
-39.9 |
-65.6 |
|
Operating expenses |
-178.7 |
-172.5 |
-328.7 |
-293.6 |
-617.9 |
|
EBIT |
-54.0 |
-13.3 |
-90.9 |
20.7 |
-19.9 |
|
EBIT margin, % |
-37.8 |
-7.4 |
-33.1 |
5.8 |
-3.0 |
|
EBITDA |
-41.1 |
-9.0 |
-65.2 |
30.1 |
19.0 |
|
Earnings per share, before dilution, SEK |
-2.15 |
-0.94 |
-3.07 |
1.44 |
-2.45 |
|
Earnings per share, after dilution, SEK |
-2.15 |
-0.94 |
-3.07 |
1.44 |
-2.45 |
|
Cash flow from operating activities |
-20.9 |
-7.2 |
-68.7 |
40.9 |
16.8 |
|
Cash and cash equivalents |
679.7 |
677.2 |
679.7 |
677.2 |
505.3 |
Net revenues and EBIT per segment Q2 2021
|
SEK m |
Net Revenues |
EBIT |
||||||||
|
2021 Apr-Jun |
2020 Apr-Jun |
2021 Jan-Jun |
2020 Jan-Jun |
2020 Jan-Dec |
2021 Apr-Jun |
2020 Apr-Jun |
2021 Jan-Jun |
2020 Jan-Jun |
2020 Jan-Dec |
|
|
ZUBSOLV® US |
126.0 |
172.5 |
252.8 |
336.4 |
623.3 |
- |
- |
- |
- |
- |
|
US Pharma – total |
126.0 |
172.5 |
252.8 |
336.4 |
623.3 |
61.6 |
88.8 |
127.7 |
164.5 |
331.2 |
|
Digital Therapeutics (DTx) product sales |
0.3 |
- |
0.4 |
- |
0.0 |
- |
- |
- |
- |
- |
|
Digital Therapeutics (DTx) – total |
0.3 |
- |
0.4 |
- |
0.0 |
-51.6 |
-35.5 |
-110.5 |
-47.6 |
-175.4 |
|
Abstral® royalties |
14.3 |
3.5 |
17.0 |
12.2 |
29.7 |
- |
- |
- |
- |
- |
|
Edluar® royalties |
2.3 |
3.1 |
4.9 |
5.5 |
10.4 |
- |
- |
- |
- |
- |
|
ZUBSOLV® - ex US |
- |
- |
- |
0.1 |
0.1 |
- |
- |
- |
- |
- |
|
HQ & Pipeline segment - total |
16.5 |
6.6 |
21.9 |
17.8 |
40.2 |
-63.9 |
-66.6 |
-108.2 |
-96.2 |
-175.8 |
|
Total |
142.8 |
179.1 |
275.1 |
354.2 |
663.6 |
-54.0 |
-13.3 |
-90.9 |
20.7 |
-19.9 |
Cash flow Q2 2021
|
SEK m |
2021 Apr-Jun |
2020 Apr-Jun |
2021 Jan-Jun |
2020 Jan-Jun |
2020 Jan-Dec |
|
Cash flow from operating activities |
-20.9 |
-7.2 |
-68.7 |
40.9 |
16.8 |
|
Investment activities |
-13.1 |
-106.0 |
-29.3 |
-109.9 |
-189.2 |
|
Financing activities |
-3.5 |
-33.9 |
258.2 |
-102.7 |
-111.3 |
|
Cash flow (excl exchange rate differences) |
-37.5 |
-147.1 |
160.1 |
-171.7 |
-283.7 |
|
Liquid funds |
679.7 |
677.2 |
679.7 |
677.2 |
505.3 |